|
41 Companies |
|
29 Products |
|
29 Products |
|
22 Mechanisms of Action |
|
2 Trials |
|
854 News |
|
| «12345678910111213...1617» |
- chloroquine phosphate / Generic mfg., primaquine / Generic mfg.
Trial completion, Enrollment change: Safety and Efficacy of Chloroquine and Primaquine for Vivax Malaria in Bhutan (clinicaltrials.gov) - May 27, 2016
P=N/A, N=24, Completed, Sponsor: Menzies School of Health Research
Active, not recruiting --> Completed | N=50 --> 24
- Coarsucam (artesunate/amodiaquine) / Sanofi, DNDi, Tivicay (dolutegravir) / ViiV Healthcare
Trial primary completion date, Combination therapy: DolACT: Dolutegravir Interactions With Artemisinin-based Combination Therapies (clinicaltrials.gov) - May 12, 2016
P1, N=46, Recruiting, Sponsor: University of Liverpool
Active, not recruiting --> Completed | N=50 --> 24 Trial primary completion date: Dec 2015 --> Jun 2016
- | Trial completion, Trial primary completion date: Safety and Immunogenicity of Plant-Derived Pfs25 VLP-FhCMB Malaria Transmission Blocking Vaccine in Healthy Adults (clinicaltrials.gov) - May 12, 2016
P1, N=44, Completed, Sponsor: Fraunhofer, Center for Molecular Biotechnology
Trial primary completion date: Dec 2015 --> Jun 2016 Active, not recruiting --> Completed | Trial primary completion date: Jun 2015 --> Aug 2014
- | chloroquine phosphate / Generic mfg., primaquine / Generic mfg.
Trial completion, Enrollment change, Trial initiation date, Trial primary completion date: Comparison Between 7 and 14 Day Primaquine Combined With Dihydroartemisinin-piperaquine or 3 Day Chloroquine Radical Cure of P. Vivax (BPD) (clinicaltrials.gov) - Apr 28, 2016
P3, N=680, Completed, Sponsor: University of Oxford
Active, not recruiting --> Completed | Trial primary completion date: Jun 2015 --> Aug 2014 Recruiting --> Completed | N=900 --> 680 | Initiation date: Jul 2012 --> Feb 2012 | Trial primary completion date: Dec 2014 --> Jul 2015
- | gentamicin sulfate / Generic mfg.
Enrollment closed: Phase 3 Study of Walter Reed (WR) 279,396 and Paromomycin Alone for the Treatment of Cutaneous Leishmaniasis in Panama (clinicaltrials.gov) - Apr 21, 2016
P3, N=400, Active, not recruiting, Sponsor: U.S. Army Medical Research and Materiel Command
Recruiting --> Completed | N=900 --> 680 | Initiation date: Jul 2012 --> Feb 2012 | Trial primary completion date: Dec 2014 --> Jul 2015 Recruiting --> Active, not recruiting
- Trial primary completion date: Comparison of Standard and Alternative Antimonial Dosage in Patients With American Cutaneous Leishmaniasis (clinicaltrials.gov) - Apr 19, 2016
P3, N=264, Active, not recruiting, Sponsor: Oswaldo Cruz Foundation
Recruiting --> Active, not recruiting Trial primary completion date: Dec 2015 --> Apr 2016
- ||| Trial completion: Safety and Protective Efficacy of Intravenous Immunization With Cryopreserved Plasmodium Falciparum Sporozoites Under Chemoprophylaxis (clinicaltrials.gov) - Apr 14, 2016
P1, N=67, Completed, Sponsor: Sanaria Inc.
Trial primary completion date: Dec 2015 --> Apr 2016 Active, not recruiting --> Completed
- Trial completion: Artemisinin-resistant Malaria in Cambodia (clinicaltrials.gov) - Apr 8, 2016
P=N/A, N=860, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- || artemether/lumefantrine / Generic mfg.
Enrollment closed: Surveillance of Effectiveness/Safety of Artemether-lumefantrine in Patients With Malaria (clinicaltrials.gov) - Apr 7, 2016
P=N/A, N=3000, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- amphotericin b liposome / Generic mfg.
Trial primary completion date, Combination therapy, Monotherapy: Efficacy Trial of Ambisome Given Alone and Ambisome Given in Combination With Miltefosine for the Treatment of VL HIV Positive Ethiopian Patients. (clinicaltrials.gov) - Mar 21, 2016
P3, N=132, Active, not recruiting, Sponsor: Drugs for Neglected Diseases
Recruiting --> Active, not recruiting Trial primary completion date: Jan 2016 --> Aug 2016
- Enrollment closed, Enrollment change, Trial primary completion date: Paracetamol Effect on Oxidative Stress and Renal Function in Severe Malaria (clinicaltrials.gov) - Mar 18, 2016
P=N/A, N=62, Active, not recruiting, Sponsor: University of Oxford
Trial primary completion date: Jan 2016 --> Aug 2016 Recruiting --> Active, not recruiting | N=50 --> 62 | Trial primary completion date: Dec 2015 --> Dec 2016
- | Eurartesim (dihydroartemisinin/piperaquine) / Medicines for Malaria Venture, Leadiant Biosci
Trial completion, Enrollment change: PRINOGAM: Primaquine's Gametocytocidal Efficacy in Malaria Asymptomatic Carriers (clinicaltrials.gov) - Mar 18, 2016
P3, N=467, Completed, Sponsor: Medical Research Council Unit, The Gambia
Recruiting --> Active, not recruiting | N=50 --> 62 | Trial primary completion date: Dec 2015 --> Dec 2016 Active, not recruiting --> Completed | N=1200 --> 467
- Inomax (nitric oxide) / Mallinckrodt
Trial completion: Evaluation of the Efficacy and Safety of Inhaled Nitric Oxide as Adjunctive Treatment for Cerebral Malaria in Children (clinicaltrials.gov) - Mar 2, 2016
P2, N=92, Completed, Sponsor: Epicentre
Active, not recruiting --> Completed | N=1200 --> 467 Recruiting --> Completed
- sodium valproate / Generic mfg.
Trial primary completion date: Pilot Trial of Valproate as Adjunctive Treatment for Toxoplasma Gondii Infection in Early Course Schizophrenia (clinicaltrials.gov) - Feb 29, 2016
P4, N=100, Enrolling by invitation, Sponsor: University of Pittsburgh
Recruiting --> Completed Trial primary completion date: Feb 2016 --> Aug 2016
- ||||||| chloroquine phosphate / Generic mfg., atovaquone/proguanil / Generic mfg., azithromycin / Generic mfg.
Trial completion: Azithromycin Plus Chloroquine Versus Atovaquone-Proguanil For The Treatment Of Uncomplicated Plasmodium Falciparum Malaria In South America (clinicaltrials.gov) - Feb 27, 2016
P2/3, N=244, Completed, Sponsor: Pfizer
Trial primary completion date: Feb 2016 --> Aug 2016 No longer recruiting --> Completed
- | Coarsucam (artesunate/amodiaquine) / Sanofi, DNDi
Trial completion, Enrollment change, Head-to-Head: Efficacy,Safety and Tolerability of Dihydroartemisinin-Piperaquine for Uncomplicated Malaria in Pregnancy in Ghana (clinicaltrials.gov) - Feb 24, 2016
P3, N=417, Completed, Sponsor: Kwame Nkrumah University of Science and Technology
No longer recruiting --> Completed Recruiting --> Completed | N=904 --> 417
- atovaquone/proguanil / Generic mfg.
Trial completion: BMGF2b: Chemoprophylaxis and Plasmodium Falciparum NF54 Sporozoite Immunization Challenged by Heterologous Infection (clinicaltrials.gov) - Feb 23, 2016
P=N/A, N=40, Completed, Sponsor: Radboud University
Recruiting --> Completed | N=904 --> 417 Active, not recruiting --> Completed
- Trial completion: Phase 1 LEISH-F3 + SLA-SE Vaccine Trial in Healthy Adult Volunteers (clinicaltrials.gov) - Feb 23, 2016
P1, N=39, Completed, Sponsor: IDRI
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Trial primary completion date: Malaria in Early Life Study (clinicaltrials.gov) - Feb 18, 2016
P=N/A, N=756, Recruiting, Sponsor: Gadjah Mada University
Active, not recruiting --> Completed Trial primary completion date: Jan 2016 --> Apr 2016
- Enrollment closed, Trial primary completion date: Topical 3% Amphotericin B Cream for the Treatment of Cutaneous Leishmaniasis in Colombia (clinicaltrials.gov) - Feb 18, 2016
P1/2, N=80, Active, not recruiting, Sponsor: Drugs for Neglected Diseases
Trial primary completion date: Jan 2016 --> Apr 2016 Recruiting --> Active, not recruiting | Trial primary completion date: Feb 2015 --> Nov 2015
- chloroquine phosphate / Generic mfg.
Trial initiation date, Trial primary completion date: Chloroquine Population Pharmacokinetics in Pre and Post-partum Women (clinicaltrials.gov) - Feb 16, 2016
P=N/A, N=160, Recruiting, Sponsor: University of Oxford
Recruiting --> Active, not recruiting | Trial primary completion date: Feb 2015 --> Nov 2015 Initiation date: Dec 2010 --> Jun 2011 | Trial primary completion date: Jan 2014 --> Jan 2017
- primaquine / Generic mfg.
Trial completion, Trial primary completion date: Primaquine Pharmacokinetics in Lactating Women and Their Infants (clinicaltrials.gov) - Feb 16, 2016
P1, N=20, Completed, Sponsor: University of Oxford
Initiation date: Dec 2010 --> Jun 2011 | Trial primary completion date: Jan 2014 --> Jan 2017 Recruiting --> Completed | Trial primary completion date: Dec 2013 --> Jul 2014
- | trimethoprim/sulfamethoxazole / Generic mfg.
Trial completion, Trial primary completion date: ISROT: Influence of Trimethoprim-Sulfamethoxazole for the Recurrence of Ocular Toxoplasmosis (clinicaltrials.gov) - Feb 12, 2016
P3, N=141, Completed, Sponsor: University of Campinas, Brazil
Recruiting --> Completed | Trial primary completion date: Dec 2013 --> Jul 2014 Recruiting --> Completed | Trial primary completion date: Oct 2011 --> Nov 2013
- Trial initiation date, Trial primary completion date: SR-M-Tz: Spatial Repellent Products for the Control of Vector Borne Diseases - Malaria - Tanzania (clinicaltrials.gov) - Feb 11, 2016
P=N/A, N=2800, Not yet recruiting, Sponsor: University of Notre Dame
Recruiting --> Completed | Trial primary completion date: Oct 2011 --> Nov 2013 Initiation date: Feb 2015 --> Mar 2016 | Trial primary completion date: Mar 2017 --> Jan 2018
- Trial initiation date, Trial primary completion date: SR-M-KEN: Spatial Repellent Products for the Control of Vector Borne Diseases - Malaria - Kenya (clinicaltrials.gov) - Feb 11, 2016
P=N/A, N=600, Not yet recruiting, Sponsor: University of Notre Dame
Initiation date: Feb 2015 --> Mar 2016 | Trial primary completion date: Mar 2017 --> Jan 2018 Initiation date: Feb 2015 --> Jun 2016 | Trial primary completion date: Mar 2017 --> Mar 2018
- Enrollment open, Enrollment change, Trial initiation date, Trial primary completion date: SR-M-IDR: Spatial Repellent Products for Control of Vector Borne Diseases - Malaria - Indonesia (clinicaltrials.gov) - Feb 11, 2016
P=N/A, N=2000, Recruiting, Sponsor: University of Notre Dame
Initiation date: Feb 2015 --> Jun 2016 | Trial primary completion date: Mar 2017 --> Mar 2018 Not yet recruiting --> Recruiting | N=1300 --> 2000 | Initiation date: Jan 2015 --> May 2015 | Trial primary completion date: Mar 2017 --> Mar 2018
- || Enrollment closed: Safety and Protective Efficacy of Intravenous Immunization With Cryopreserved Plasmodium Falciparum Sporozoites Under Chemoprophylaxis (clinicaltrials.gov) - Feb 8, 2016
P1, N=67, Active, not recruiting, Sponsor: Sanaria Inc.
Not yet recruiting --> Recruiting | N=1300 --> 2000 | Initiation date: Jan 2015 --> May 2015 | Trial primary completion date: Mar 2017 --> Mar 2018 Recruiting --> Active, not recruiting
- | Trial completion: Prophylaxis of Visceral Leishmaniasis Relapses in HIV Co-infected Patients With Pentamidine: a Cohort Study (clinicaltrials.gov) - Feb 5, 2016
P3, N=72, Completed, Sponsor: Institute of Tropical Medicine, Belgium
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- DSM265 / Medicines for Malaria Venture
Trial completion, Trial initiation date, Trial primary completion date: DSM265 Phase IIa Investigation Treating Plasmodium Falciparum or Vivax (clinicaltrials.gov) - Feb 2, 2016
P2a, N=45, Completed, Sponsor: Medicines for Malaria Venture
Active, not recruiting --> Completed Active, not recruiting --> Completed | Initiation date: Jan 2015 --> Jan 2016 | Trial primary completion date: Apr 2016 --> Jan 2016
- Trial completion, Trial primary completion date: Safety and Immunogenicity of Recombinant Pichia Pastoris AMA1-DiCo Candidate Malaria Vaccine With GLA-SE and Alhydrogel (clinicaltrials.gov) - Feb 2, 2016
P1, N=66, Completed, Sponsor: Institut National de la Sant
Active, not recruiting --> Completed | Initiation date: Jan 2015 --> Jan 2016 | Trial primary completion date: Apr 2016 --> Jan 2016 Active, not recruiting --> Completed | Trial primary completion date: Jun 2015 --> Mar 2015
- | primaquine / Generic mfg., artemether/lumefantrine / Generic mfg.
Trial completion, Trial primary completion date, Combination therapy: Safety of Primaquine + Artemether-lumefantrine in G6PD Deficient Males With an Asymptomatic Malaria Infection (SAFEPRIM) (clinicaltrials.gov) - Feb 2, 2016
P2/3, N=70, Completed, Sponsor: London School of Hygiene and Tropical Medicine
Active, not recruiting --> Completed | Trial primary completion date: Jun 2015 --> Mar 2015 Recruiting --> Completed | Trial primary completion date: Sep 2015 --> Dec 2015
- Trial completion: VAST: Comparing NAAT Testing to Standard Methods for the Diagnosis of Vaginitis (clinicaltrials.gov) - Jan 27, 2016
P=N/A, N=300, Completed, Sponsor: University of Pittsburgh
Recruiting --> Completed | Trial primary completion date: Sep 2015 --> Dec 2015 Recruiting --> Completed
- Enrollment closed, Trial primary completion date: NIDIAGDigest: Diagnosis of Neglected Tropical Diseases Among Patients With Persistent Digestive Disorders (clinicaltrials.gov) - Jan 26, 2016
P=N/A, N=4000, Active, not recruiting, Sponsor: Swiss Tropical & Public Health Institute
Recruiting --> Completed Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2015 --> Mar 2016
- Mefliam Plus (artesunate/mefloquine) / Cipla, Oswaldo Cruz Foundation, DNDi
Trial completion, Enrollment change, Trial primary completion date, Combination therapy: Harmonized AS/MQ Efficacy Study - Thailand (clinicaltrials.gov) - Jan 25, 2016
P4, N=48, Completed, Sponsor: Armed Forces Research Institute of Medical Sciences, Thailand
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2015 --> Mar 2016 Recruiting --> Completed | N=100 --> 48 | Trial primary completion date: Jul 2015 --> Oct 2015
- Trial completion, HEOR: Impact of a Parenting Program in Liberia to Improve Parenting, Education, and Health Outcomes for Children in Liberia (clinicaltrials.gov) - Jan 25, 2016
P=N/A, N=270, Completed, Sponsor: International Rescue Committee
Recruiting --> Completed | N=100 --> 48 | Trial primary completion date: Jul 2015 --> Oct 2015 Active, not recruiting --> Completed
- amphotericin b liposome / Generic mfg.
Enrollment change, Trial primary completion date: Open-Label, Sequential Step, Safety and Efficacy Study to Determine the Optimal Single Dose of Ambisome for Patients With VL (clinicaltrials.gov) - Jan 21, 2016
P2, N=124, Terminated, Sponsor: Drugs for Neglected Diseases
Active, not recruiting --> Completed N=240 --> 124 | Trial primary completion date: Jun 2011 --> Sep 2010
- | amphotericin b liposome / Generic mfg.
Trial completion, Trial primary completion date: Phase III, Study of Three Short Course Combo (Ambisome (clinicaltrials.gov) - Jan 21, 2016
P3, N=602, Completed, Sponsor: Drugs for Neglected Diseases
N=240 --> 124 | Trial primary completion date: Jun 2011 --> Sep 2010 Recruiting --> Completed | Trial primary completion date: Dec 2011 --> Mar 2014
- TicoVac (tick-borne encephalitis vaccine, whole Virus inactivated) / Pfizer
Trial primary completion date: Vaccine Study for Tick-Borne Encephalitis Virus (TBEV) (clinicaltrials.gov) - Jan 17, 2016
P2, N=160, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Completed | Trial primary completion date: Dec 2011 --> Mar 2014 Trial primary completion date: Jan 2030 --> Nov 2020
- | primaquine / Generic mfg.
Trial completion, Combination therapy: DAPPI: Dihydroartemisinin-piperaquine With Low Dose Primaquine to Reduce Malaria Transmission (clinicaltrials.gov) - Jan 15, 2016
P3, N=120, Completed, Sponsor: London School of Hygiene and Tropical Medicine
Trial primary completion date: Jan 2030 --> Nov 2020 Recruiting --> Completed
- trimethoprim/sulfamethoxazole / Generic mfg.
Trial completion, Trial primary completion date: Impact of TMP-SMX Prophylaxis on Malaria Infection and Immunity in Children in Uganda (clinicaltrials.gov) - Dec 31, 2015
P=N/A, N=400, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Completed Not yet recruiting --> Completed | Trial primary completion date: Nov 2016 --> Dec 2015
- Euvax B (recombinant hepatitis B vaccine) / LG Chem, Menactra (Meningococcal-groups A, C, Y and W-135 polysaccharide diphtheria toxoid conjugate vaccine) / Sanofi
Trial completion, Trial primary completion date: Testing Pfs25-EPA/Alhydrogel as a Potential Malaria Transmission Blocking Vaccine (clinicaltrials.gov) - Dec 25, 2015
P1, N=350, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting --> Completed | Trial primary completion date: Nov 2016 --> Dec 2015 Active, not recruiting --> Completed | Trial primary completion date: Jun 2016 --> Dec 2015
- Trial completion: Bihar Evaluation of Social Franchising and Telemedicine (clinicaltrials.gov) - Dec 16, 2015
P=N/A, N=106380, Completed, Sponsor: Duke University
Active, not recruiting --> Completed | Trial primary completion date: Jun 2016 --> Dec 2015 Active, not recruiting --> Completed
- || Trial primary completion date: Ph 2B/3 Tafenoquine (TFQ) Study in Prevention of Vivax Relapse (clinicaltrials.gov) - Dec 16, 2015
P2, N=924, Recruiting, Sponsor: GlaxoSmithKline
Active, not recruiting --> Completed Trial primary completion date: Oct 2015 --> Nov 2016
- Trial completion, Trial primary completion date: Innovative Public-private Partnership to Target Subsidized Antimalarials in the Retail Sector (clinicaltrials.gov) - Dec 15, 2015
P=N/A, N=444, Completed, Sponsor: Duke University
Trial primary completion date: Oct 2015 --> Nov 2016 Recruiting --> Completed | Trial primary completion date: Jul 2016 --> Jul 2015
- Biomarker, Enrollment closed: BIOMARCHA: New Tools for the Diagnosis, Prognosis and Treatment Follow-up in Chagas Disease (clinicaltrials.gov) - Dec 12, 2015
P=N/A, N=63, Active, not recruiting, Sponsor: Barcelona Centre for International Health Research
Recruiting --> Completed | Trial primary completion date: Jul 2016 --> Jul 2015 Recruiting --> Active, not recruiting
- atovaquone/proguanil / Generic mfg., artemether/lumefantrine / Generic mfg.
Trial completion: Evaluation of the Riamet (clinicaltrials.gov) - Dec 10, 2015
P4, N=317, Completed, Sponsor: Assistance Publique - H
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- trimethoprim/sulfamethoxazole / Generic mfg.
Trial primary completion date: Impact of TMP-SMX Prophylaxis on Malaria Infection and Immunity in Children in Uganda (clinicaltrials.gov) - Dec 9, 2015
P=N/A, N=400, Not yet recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed Trial primary completion date: Nov 2015 --> Nov 2016
- DSM265 / Medicines for Malaria Venture
Enrollment closed, Enrollment change: DSM265 Phase IIa Investigation Treating Plasmodium Falciparum or Vivax (clinicaltrials.gov) - Dec 5, 2015
P2a, N=45, Active, not recruiting, Sponsor: Medicines for Malaria Venture
Trial primary completion date: Nov 2015 --> Nov 2016 Recruiting --> Active, not recruiting | N=60 --> 45
- Menactra (Meningococcal-groups A, C, Y and W-135 polysaccharide diphtheria toxoid conjugate vaccine) / Sanofi, Twinrix (inactivated hepatitis A and recombinant hepatitis B) / GSK
Enrollment closed, Enrollment change: Study of the Safety and Immunogenicity of Pfs230D1M-EPA/Alhydrogel and Pfs25M-EPA/Alhydrogel , a Transmission Blocking Vaccine Against Plasmodium Falciparum Malaria, in Adults in the U.S. and Mali (clinicaltrials.gov) - Dec 5, 2015
P1, N=54, Active, not recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Active, not recruiting | N=60 --> 45 Recruiting --> Active, not recruiting | N=850 --> 54
- Enrollment change, Trial termination, Trial primary completion date: High Dose Fluconazole in Cutaneous Leishmaniasis in Bahia and Manaus (clinicaltrials.gov) - Dec 4, 2015
P3, N=53, Terminated, Sponsor: Hospital Universit
Recruiting --> Active, not recruiting | N=850 --> 54 N=140 --> 53 | Not yet recruiting --> Terminated | Trial primary completion date: Dec 2014 --> Apr 2015; Low cure rate in the study (fluconazole) group